Lifecore Biomedical — Third Quarter 2026 Earnings Summary

Lifecore Biomedical reported a net loss of $40.1 million for the third quarter of 2026, driven by a $31.3 million non-cash charge related to changes in the fair value of debt derivative liabilities. Total revenues for the quarter declined 18.6% to $25.3 million, while operating expenses decreased by 28.9% to $7.7 million. Despite the quarterly loss, the company generated $9.5 million in cash from operations and $6.9 million in free cash flow for the first nine months of the year. The firm also announced the acquisition of two new technology transfer projects and three new development-phase programs expected to contribute to revenue growth starting in 2027.